tbuckley/cabot-search huggingface dataset:
A simple, universal and multifunctional template agent for personalized treatment of bone tumors
Authors: Wei-bo Liu, Su-he Dong, Wen-hao Hu, Meng Gao, Teng Li, Quan-bo Ji, Xiao-qing Yang, Deng-bin Qi, Zhen Zhang, Ze-Long Song, Yu-jie Liu, Xue-song Zhang
Journal: Bioactive Materials (2021)

Bone tumors occur in bone or its accessory tissues. Benign bone tumors are easy to cure and have good prognosis, while malignant bone tumors develop rapidly and have poor and high mortality. So far, there is no satisfactory treatment method. Here, we designed a universal template vector for bone tumor therapy that simultaneously meets the needs of bone targeting, tumor killing, osteoclast suppression, and tumor imaging. The template is composed of a polydopamine (PDA) core and a multifunctional surface. PDA has excellent biosafety and photothermal performance. In this study, alendronate sodium (ALN) is grafted to enable its general bone targeting function. PDA core can carry a variety of chemotherapy drugs, and the rich ALN group can carry a variety of metal ions with an imaging function. Therefore, more personalized treatment plans can be designed for different bone tumor patients. In addition, the PDA core enables photothermal therapy and enhanced chemotherapy. Through template drug Doxorubicin (DOX) and template imaging ion Fe (Ⅱ), we systematically verified the therapeutic effect, imaging effect, and inhibition of bone dissolution of the agent on Osteosarcoma (OS), a primary malignant bone tumor, in vivo. In conclusion, our work provides a more general template carrier for the clinical treatment of bone tumors, through which personalized treatment of bone tumors can be achieved.
Iron deficiency and fatigue among adolescents with bleeding disorders
Authors: Ayesha Zia, Joseph Stanek, Myra Christian‐Rancy, Stephanie Savelli, Sarah H. O'Brien
Journal: American Journal of Hematology (2021)

Iron deficiency anemia is associated with heavy menstrual bleeding (HMB) and, by extension, a bleeding disorder (BD). It is unknown if iron deficiency without anemia is associated with a BD in adolescents. Moreover, the threshold of ferritin associated with fatigue in adolescents with HMB is unclear. In this multicenter study, we enrolled adolescents with HMB without BD. Participants underwent BD and anemia work-up in Young Women's Hematology Clinics and completed the Peds QL™ fatigue scale. BDs were defined as von Willebrand Disease, platelet function defect, clotting factor deficiencies, and hypermobility syndrome. Two hundred and fifty consecutive adolescents were enrolled, of whom 196 met eligibility criteria. Overall, 43% (95% confidence interval: 36%-50%) were diagnosed with BD. A total of 61% (n = 119) had serum ferritin levels < 15 ng/mL, 23.5% (n = 46) had iron deficiency only, and 37% (n = 73) had iron deficiency anemia. Low ferritin or ferritin dichotomized as < 15 or ≥ 15 ng/mL was not associated with BD on univariable analysis (p = .24) or when accounting for age, race, ethnicity, body mass index, and hemoglobin (p = .35). A total of 85% had total fatigue score below the population mean of 80.5, and 52% (n = 102) were > 2 SD (or < 54) below the mean, the cut-off associated with severe fatigue. A ferritin threshold of < 6 ng/mL had a specificity of 79.8% but a sensitivity of 36% for severe fatigue. In conclusion, iron deficiency without anemia is not a predictor of BD in adolescents with HMB in a specialty setting. Severe fatigue, especially sleep fatigue, is prevalent in adolescents with BD. Ferritin of < 6 ng/mL has ~80% specificity for severe fatigue in adolescents with HMB.
Engineering injectable vascularized tissues from the bottom-up: Dynamics of in-gel extra-spheroid dermal tissue assembly
Authors: Tália Feijão, Mariana I. Neves, Aureliana Sousa, Ana L. Torres, Sílvia J. Bidarra, Iasmim D. Orge, Daniel T.O. Carvalho, Cristina C. Barrias
Journal: Biomaterials (2021)
TCT-225 Fractional Flow Reserve– or Angiography-Guided Revascularization for ST-Elevation Myocardial Infarction With Multivessel Disease: A Systematic Review and Network Meta-Analysis of Randomized Trials
Authors: Ali Omar, Hiroki Ueyama, Hisato Takagi, Toshiki Kuno
Journal: Journal of the American College of Cardiology (2021)
One-Year Experience of COVID-19 Disease of 700 Chronic Dialysis Patients from Ecuadorian Highlands
Authors: Juan C. Santacruz, Ana K. Vásquez Perez, Carlotta Sulbaran, Paulo Reinoso, Maria G. Santacruz, Angel C. Santacruz
Journal: Journal of the American Society of Nephrology (2021)

Santacruz, Juan C.; Vásquez Perez, Ana K.; Sulbaran, Carlotta; Reinoso, Paulo; Santacruz, Maria G.; Santacruz, Angel C. Author Information
TCT-41 Treatment and Outcomes of Aortic Stenosis in Elderly Patients in the United States: Temporal Trends and Age Differences
Authors: Alexis Okoh, Ankur Sethi, Molly Szerlip, Michael Mack, Tsuyoshi Kaneko, Tom Nguyen, Isaac George, Vinod Thourani, Leonard Lee, Mark Russo
Journal: Journal of the American College of Cardiology (2021)
TCT-247 Diagnostic Accuracy of Quantitative Flow Ratio for Assessment of Coronary Stenosis Significance From a Single Angiographic View: A Novel Method Based on Bifurcation Fractal Law
Authors: Shengxian Tu, Daixin Ding, Yunxiao Chang, Chunming Li, William Wijns, Bo Xu
Journal: Journal of the American College of Cardiology (2021)
Radiology Imaging of Bronchiectasis in Children and Adolescents (Literature Review with Own Observations)
Authors: P. V. Gavrilov
Journal: Radiology - Practice (2021)

Timely detection of bronchiectasis in children is of great prognostic value. The importance of modern bronchiectasis in children is due to their possible reversibility over time with effective treatment, as well as a number of significant differences between bronchiectasis in childhood and onset in children, which may reflect different phenotypes of bronchiectasis. In adult patients with bronchiectasis that began in childhood, the pathological process has a more severe and worse prognosis compared to bronchiectasis that began in adulthood. In 2020, the European Respiratory Society proposed a new formulation of the terminal «bronchiectasis» for children and adolescents, now this term refers to an abnormal expansion of the bronchi by computed tomography (CT) of the chest, which, if detected early, can be reversible. CT is the true «gold standard» for confirming bronchiectasis in children and adolescents. This method is included in the minimum set of tests for children and adolescents with suspected bronchiectasis according to the recommendations of the European Respiratory Society. When conducting CT, it is recommended to perform a continuous spiral scan with a collimation of 1 mm, the study is carried out without intravenous use using low-dose protocols. To assess the state of the bronchi in children and adolescents, it is necessary to use the pediatric norms of the broncho-arterial ratio (&gt; 0.8). At the same time, radiation methods are not decisive in establishing the causes of bronchiectasis and only in rare cases can help in establishing bronchiectasis. Dynamic observation of bronchiectasis for children and adolescents is determined individually. Consideration should be given to repeat chest computed tomography scans to answer the question that will change treatment.
TCT-356 Safety and Efficacy of Transcatheter Aortic Valve Implantation in Stenotic Bicuspid Aortic Valve: A Meta-Analysis
Authors: Mohamed Zghouzi, Waqas Ullah, Heba Osman, Mukhlis Abdalrazzak, Abdul-Rahman Suleiman, Bachar Ahmad, Firas Rabbat, Adam Chalek, Chaitu Dandu, Parveen Razvi, Yasar Sattar, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2021)
Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma
Authors: Xiaoji Ma, Yikuan Chen, Wanxiangfu Tang, Hua Bao, Shaobo Mo, Rui Liu, Shuyu Wu, Hairong Bao, Yaqi Li, Long Zhang, Xue Wu, Sanjun Cai, Yang Shao, Fangqi Liu, Junjie Peng
Journal: Journal of Hematology & Oncology (2021)

Previous studies on liquid biopsy-based early detection of advanced colorectal adenoma (advCRA) or adenocarcinoma (CRC) were limited by low sensitivity. We performed a prospective study to establish an integrated model using fragmentomic profiles of plasma cell-free DNA (cfDNA) for accurately and cost-effectively detecting early-stage CRC and advCRA. The training cohort enrolled 310 participants, including 149 early-stage CRC patients, 46 advCRA patients and 115 healthy controls. Plasma cfDNA samples were prepared for whole-genome sequencing. An ensemble stacked model differentiating healthy controls from advCRA/early-stage CRC patients was trained using five machine learning models and five cfDNA fragmentomic features based on the training cohort. The model was subsequently validated using an independent test cohort (N = 311; including 149 early-stage CRC, 46 advCRA and 116 healthy controls). Our model showed an area under the curve (AUC) of 0.988 for differentiating advCRA/early-stage CRC patients from healthy individuals in an independent test cohort. The model performed even better for identifying early-stage CRC (AUC 0.990) compared to advCRA (AUC 0.982). At 94.8% specificity, the sensitivities for detecting advCRA and early-stage CRC reached 95.7% and 98.0% (0: 94.1%; I: 98.5%), respectively. Promisingly, the detection sensitivity has reached 100% and 97.6% in early-stage CRC patients with negative fecal occult or CEA blood test results, respectively. Finally, our model maintained promising performances (AUC: 0.982, 94.4% sensitivity at 94.8% specificity) even when sequencing depth was down-sampled to 1X. Our integrated predictive model demonstrated an unprecedented detection sensitivity for advCRA and early-stage CRC, shedding light on more accurate noninvasive CRC screening in clinical practice.
Prognostic Implications of Post-Intervention Resting Pd/Pa and Fractional Flow Reserve in Patients With Stent Implantation
Authors: Shin, D[Shin, Doosup], Lee, SH[Lee, Seung Hun], Lee, JM[Lee, Joo Myung], Choi, KH[Choi, Ki Hong], Hwang, D[Hwang, Doyeon], Lee, H[Lee, Hyunjong], Jang, HJ[Jang, Ho-Jun], Kim, HK[Kim, Hyun Kuk], Kwak, JJ[Kwak, Jae-Jin], Ha, SJ[Ha, Sang Jin], Song, YB[Song, Young Bin], Shin, ES[Shin, Eun-Seok], Doh, JH[Doh, Joon-Hyung]
Journal: Journal of the American College of Cardiology (2020)
Abstract 21407: Effect of Aspiration Thrombectomy on in Hospital Mortality in Patients With ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the U.S National Inpatient Sample Database
Authors: Venkat Vuddanda, Mohit K. Turagam, Srikanth Yandrapalli, Atul Singla, Natraj Katta, Sudarshan Balla
Journal: Circulation (2017)

Introduction: Aspiration thrombectomy (AT) during percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been widely used. Recent large multicenter trials have created uncertainty about the benefit of thrombus aspiration and suggested possible harm from increased stroke risk. There is lack of real world data regarding outcomes with AT when performed in addition to PCI of the culprit artery for STEMI. Hypothesis: We sought to investigate the effect of AT on in-hospital mortality when performed in addition to culprit artery PCI for STEMI. Methods: Using the U.S. National Inpatient Sample (NIS) database from 2007-14, we identified all discharge records with a primary diagnosis of STEMI (ICD-9-CM diagnosis codes 410.XX) undergoing PCI (ICD-9-CM procedure codes 00.66, and 36.0X). Patients receiving AT in addition to PCI during the hospitalization were identified using ICD-9-CM procedure code 36.09, and in-hospital mortality was compared in patients with and without AT. Statistical analyses were performed using R (Vienna, Austria). To account for the single cluster stratified random sampling design of NIS, R survey package was used to obtain national estimates. Proportions were compared with Chi-Square test, and p trend computed using Mann-Kendall test. Results: Of 951,322 PCIs for STEMI, 4299 (0.4%) had AT in addition to PCI. Use of AT remained consistent over the study period (0.53% vs. 0.70%; p trend = 0.896). We observed no statistically significant difference in the age adjusted in-hospital mortality in patients with and without AT (3.8% vs. 4.4 %; p = 0.06). Conclusion: In this nationally representative study population, aspiration thrombectomy is not associated with improvement in in-hospital mortality when performed in addition to PCI of the culprit artery for STEMI.
Fungal biomarker monitoring and CT scans for early detection of invasive fungal disease in neutropenic hematological patients
Authors: Shun-Ichi Kimura, Yoshinobu Kanda, Tatsuo Oyake, Hiroki Yamaguchi, Shin-Ichiro Fujiwara, Akinao Okamoto, Hiroyuki Fujita, Yoshio Saburi, Kazuo Tamura
Journal: Journal of Infection (2021)
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study
Authors: James S McCarthy, Özkan Yalkinoglu, Anand Odedra, Rebecca Webster, Claude Oeuvray, Aliona Tappert, Deon Bezuidenhout, Marla J Giddins, Satish K Dhingra, David A Fidock, Louise Marquart, Lachlan Webb, Xiaoyan Yin, Akash Khandelwal, Wilhelmina M Bagchus
Journal: The Lancet Infectious Diseases (2021)

M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy volunteers.
Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
Authors: Ravi Goud, Bradley Lufkin, Jonathan Duffy, Barbee Whitaker, Hui-Lee Wong, Jiemin Liao, An-Chi Lo, Shruti Parulekar, Paula Agger, Steven A. Anderson, Michael Wernecke, Thomas E. MaCurdy, Eric Weintraub, Jeffrey A. Kelman, Richard A. Forshee
Journal: JAMA Internal Medicine (2021)

Guillain-Barré syndrome can be reported after vaccination. This study assesses the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart.Use Medicare claims data to evaluate risk of developing Guillain-Barré syndrome following vaccination with zoster vaccine.This case series cohort study included 849 397 RZV-vaccinated and 1 817 099 zoster vaccine live (ZVL or Zostavax)-vaccinated beneficiaries aged 65 years or older. Self-controlled analyses included events identified from 2 113 758 eligible RZV-vaccinated beneficiaries 65 years or older. We compared the relative risk of Guillain-Barré syndrome after RZV vs ZVL, followed by claims-based and medical record-based self-controlled case series analyses to assess risk of Guillain-Barré syndrome during a postvaccination risk window (days 1-42) compared with a control window (days 43-183). In self-controlled analyses, RZV vaccinees were observed from October 1, 2017, to February 29, 2020. Patients were identified in the inpatient, outpatient procedural (including emergency department), and office settings using Medicare administrative data.Vaccination with RZV or ZVL vaccines.Guillain-Barré syndrome was identified in Medicare administrative claims data, and cases were assessed through medical record review using the Brighton Collaboration case definition.Amongst those who received RZV vaccinees, the mean age was 74.8 years at first dose, and 58% were women, whereas among those who received the ZVL vaccine, the mean age was 74.3 years, and 60% were women. In the cohort analysis we detected an increase in risk of Guillain-Barré syndrome among RZV vaccinees compared with ZVL vaccinees (rate ratio [RR], 2.34; 95% CI, 1.01-5.41; P = .047). In the self-controlled analyses, we observed 24 and 20 cases during the risk and control period, respectively. Our claims-based analysis identified an increased risk in the risk window compared with the control window (RR, 2.84; 95% CI, 1.53-5.27; P = .001), with an attributable risk of 3 per million RZV doses (95% CI, 0.62-5.64). Our medical record-based analysis confirmed this increased risk (RR, 4.96; 95% CI, 1.43-17.27; P = .01).Findings of this case series cohort study indicate a slightly increased risk of Guillain-Barré syndrome during the 42 days following RZV vaccination in the Medicare population, with approximately 3 excess Guillain-Barré syndrome cases per million vaccinations. Clinicians and patients should be aware of this risk, while considering the benefit of decreasing the risk of herpes zoster and its complications through an efficacious vaccine, as risk-benefit balance remains in favor of vaccination.
Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
Authors: Michael Pavlides, Ferenc E. Mózes, Stephen A. Harrison
Journal: Gut (2021)

Table 1 Number of patients with fibrosis stage F0-2, F3 and F4 according to LSM cut-offs recommended by the Baveno 6 consensus (10 and 15 kPa) and our previous paper (8 and 20, and 8 and 28 kPa) LSM <10 kPa LSM≥10 and < 15 kPa LSM≥15 kPa F0-2 3135
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Authors: Jie Li, Xinya Gao, Zhanqiang Zhang, Yuanhui Lai, Xunxun Lin, Bo Lin, Maoguang Ma, Xiaoli Liang, Xixi Li, Weiming Lv, Ying Lin, Nu Zhang
Journal: Molecular Cancer (2021)

Emerging studies have revealed the potent functions of circRNAs in breast cancer tumorigenesis. However, the biogenesis, biofunction and mechanism of circRNAs in triple-negative breast cancer (TNBC) are largely unknown.High-throughput RNA sequencing was applied to identify dysregulated circRNAs in TNBCs and paired normal tissues. RNA pulldown and luciferase assays were performed to investigate the interaction between circular CD44 (circCD44, also annotated as hsa_circ_0021735) and miR-502-5p. RNA pulldown and RIP assays were used to investigate the interaction between circCD44 and IGF2BP2. Cell viability, colony formation, migration/invasion assays and in vivo tumorigenesis were used to investigate circCD44 biological functions.CircCD44 is an uncharacterized circRNA, which is highly expressed in TNBC, and its expression is negatively correlated with the prognosis of TNBC patients. CircCD44 promotes TNBC proliferation, migration, invasion and tumorigenesis at least partially by sponging miR-502-5p and interacting with IGF2BP2.Our data suggested that overexpressed circCD44 promotes TNBC progression. CircCD44 is potentially a novel diagnostic and therapeutic marker for TNBC patients.
Universal Depression Screening in Schools—Promises and Challenges in Addressing Adolescent Mental Health Need
Authors: Sisi Guo, Grace Bai Jhe
Journal: JAMA Network Open (2021)

Deepa L. Sekhar, MD, MSc; Eric W. Schaefer, MS; James G. Waxmonsky, MD; Leslie R. Walker-Harding, MD; Krista L. Pattison, MS; Alissa Molinari, MPH; Perri Rosen, PhD; Jennifer L. Kraschnewski, MD, MPH
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
Authors: Brechje de Gier, Stijn Andeweg, Jantien A Backer, Susan JM Hahné, Susan van den Hof, Hester E de Melker, Mirjam J Knol
Journal: Eurosurveillance (2021)

We estimated SARS-CoV-2 vaccine effectiveness against onward transmission by comparing secondary attack rates among household members for vaccinated and unvaccinated index cases, based on source and contact tracing data collected when the Delta variant was dominant. Effectiveness of full vaccination of the index case against transmission to unvaccinated and fully vaccinated household contacts, respectively, was 63% (95% confidence interval (CI): 46–75) and 40% (95% CI: 20–54), in addition to the direct protection of vaccination of contacts against infection.
Bone marrow runs the (bone) show
Authors: Gerard Karsenty
Journal: The Journal of Experimental Medicine (2021)

In this issue of JEM, a paper by Kim et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20211872), asking a simple question through a remarkable alliance of human and mouse genetics, demonstrates that a prevalent hematological condition can lead to osteoporosis. This work is important by virtue of the quality of its results and its implication for the relationship between bone and its marrow.
Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data
Authors: Lucy A McNamara, Ryan E Wiegand, Rachel M Burke, Andrea J Sharma, Michael Sheppard, Jennifer Adjemian, Farida B Ahmad, Robert N Anderson, Kamil E Barbour, Alison M Binder, Sharoda Dasgupta, Deborah L Dee, Emma S Jones, Jennifer L Kriss, B Casey Lyons, Meredith McMorrow, Daniel C Payne, Hannah E Reses, Loren E Rodgers, David Walker, Jennifer R Verani, Stephanie J Schrag
Journal: The Lancet (2021)

In the USA, COVID-19 vaccines became available in mid-December, 2020, with adults aged 65 years and older among the first groups prioritised for vaccination. We estimated the national-level impact of the initial phases of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older.We analysed population-based data reported to US federal agencies on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 50 years and older during the period Nov 1, 2020, to April 10, 2021. We calculated the relative change in incidence among older age groups compared with a younger reference group for pre-vaccination and post-vaccination periods, defined by the week when vaccination coverage in a given age group first exceeded coverage in the reference age group by at least 1%; time lags for immune response and time to outcome were incorporated. We assessed whether the ratio of these relative changes differed when comparing the pre-vaccination and post-vaccination periods.The ratio of relative changes comparing the change in the COVID-19 case incidence ratio over the post-vaccine versus pre-vaccine periods showed relative decreases of 53% (95% CI 50 to 55) and 62% (59 to 64) among adults aged 65 to 74 years and 75 years and older, respectively, compared with those aged 50 to 64 years. We found similar results for emergency department visits with relative decreases of 61% (52 to 68) for adults aged 65 to 74 years and 77% (71 to 78) for those aged 75 years and older compared with adults aged 50 to 64 years. Hospital admissions declined by 39% (29 to 48) among those aged 60 to 69 years, 60% (54 to 66) among those aged 70 to 79 years, and 68% (62 to 73), among those aged 80 years and older, compared with adults aged 50 to 59 years. COVID-19 deaths also declined (by 41%, 95% CI -14 to 69 among adults aged 65-74 years and by 30%, -47 to 66 among those aged ≥75 years, compared with adults aged 50 to 64 years), but the magnitude of the impact of vaccination roll-out on deaths was unclear.The initial roll-out of the US COVID-19 vaccination programme was associated with reductions in COVID-19 cases, emergency department visits, and hospital admissions among older adults.None.